Investigational cancer drugs targeting cell metabolism in clinical development

Expert Opinion on Investigational Drugs

Volumn 24, Issue 1, 2015, Pages 79-94

  Sborov, Douglas W ^a   Haverkos, Bradley M ^a   Harris, Pamela J ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Cell metabolism; Drugs; Metabolism modulating agents; Phase I and II

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; FATTY ACID; REACTIVE OXYGEN METABOLITE;

AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL METABOLISM; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; EVIDENCE BASED PRACTICE; FATTY ACID SYNTHESIS; GLYCOLYSIS; HUMAN; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 84916613065     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.960077     Document Type: Article

References (103)

1. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11(2):85-95
2. Warburg O. On the origin of cancer cells. Science 1956;123(3191):309-14
3. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7(1):11-20
4. Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 2013;45(10):e45
5. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202(3):654-62
6. Dhanalakshmi S, Singh R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005;24(7):1188-202
7. Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybinphytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;70(8):848-55
8. Siegel AB, Narayan R, Rodriguez R, et al. A Phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther 2014;13(1):46-53
9. Kim JW, Gao P, Liu YC, et al. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007;27(21):7381-93
10. Pelicano H, Martin D, Xu R, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25(34):4633-46
11. Fang J, Quinones QJ, Holman TL, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for highrisk neuroblastoma. Mol Pharmacol 2006;70(6):2108-15
12. Floridi A, Bruno T, Miccadei S, et al. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharmacol 1998;56(7):841-9
13. De Lena M, Lorusso V, Latorre A, et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 2001;37(3):364-8
14. Portalone L, Lombardi A, Antilli A, et al. Treatment of inoperable non-small cell lung carcinoma stage IIIb and IV with cisplatin, epidoxorubicin, vindesine and lonidamine: a phase II study. Tumori 1998;85(4):239-42
15. Berruti A, Bitossi R, Gorzegno G, et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol 2002;20(20):4150-9
16. Pacini P, Rinaldini M, Algeri R, et al. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. Eur J Cancer 2000;36(8):966-75
17. Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-Dglucose for improving cancer therapy. Future Oncol 2009;5(5):581-5
18. Landau BR, Laszlo J, Stengle J, Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958;21(3):485-94
19. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-Dglucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004;53(2):116-22
20. Dwarakanath BS, Singh D, Banerji AK, et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther 2009;5(Suppl 1):S21-6
21. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005;181(8):507-14
22. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452(7184):230-3
23. Zhou W, Liotta LA, Petricoin EF. Cancer metabolism and mass spectrometry-based proteomics. Cancer Lett 2013. [Epub ahead of print]
24. Wong N, De Melo J, Tang D. PKM2, a central point of regulation in cancer metabolism. Int J Cell Biol 2013;2013:242513
25. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013;12(11):829-46
26. Fujiwara S, Kawano Y, Yuki H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer 2013;108(1):170-8
27. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008;99(7):989-94
28. Whitehouse S, Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 1974;141(3):761-74
29. Dunbar E, Coats B, Shroads A, et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 2014;32(3):452-64
30. Shroads AL, Langaee T, Coats BS, et al. Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol 2012;52(6):837-49
31. Garon EB, Christofk HR, Hosmer W, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced nonsmall cell lung cancer. J Cancer Res Clin Oncol 2014;140(3):443-52
32. Xuan Y, Hur H, Ham IH, et al. Dichloroacetate attenuates hypoxiainduced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism. Exp Cell Res 2014;321(2):219-30
33. Stuart SD, Schauble A, Gupta S, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab 2014;2(1):4
34. Zachar Z, Marecek J, Maturo C, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med 2011;89(11):1137-48
35. Pardee T, Lee K, Luddy J, et al. A phase I study of the safety, efficacy and pharmacokinetics of the first in class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies. Blood 2013;122(21):A486
36. Lee K, Khaira D, Rodriguez R, et al. Long-term stable disease of stage IV pancreatic neuroendocrine tumors and without significant adverse effect by CPI- 613, an investigational novel anti-cancer agent. Case Stud Case Rep 2011;1:137-45
37. Senzer N, Bedell C, Maturo C, et al. CPI-613, an investigational novel anticancer agent, provides long-term stable disease without significant adverse effects in a patient with stage IV relapsed hepatocellular carcinoma. Case Stud Case Rep 2012;2(2):38-45
38. Dimmer KS, Friedrich B, Lang F, et al. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000;350(Pt 1):219-27
39. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010;6(1):127-48
40. Egler RA, Fernandes E, Rothermund K, et al. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 2005;24(54):8038-50
41. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996;10(7):709-20
42. Doroshow JH. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst 2006;98(4):223-5
43. Kawecki A, Adkins D, Cunningham C, et al. A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2007;25:16509
44. Shapiro G, Supko J, Ryan D, et al. Phase I trial of ARQ 501, an activated checkpoint therapy (ACT) agent, in patients with advanced solid tumors. J Clin Oncol 2005;23:3042
45. Khong H, Dreisbach L, Kindler H, et al. A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:15017
46. Nagai M, Vo NH, Shin Ogawa L, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med 2012;52(10):2142-50
47. ODay S, Gonzalez R, Lawson D, et al. Phase II, randomized, controlled, doubleblinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009;27(32):5452-8
48. ODay SJ, Eggermont AM, Chiarion-Sileni V, et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapynaive patients with advanced melanoma. J Clin Oncol 2013;31(9):1211-18
49. Khan G, Merajver S. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs 2009;18(4):541-8
50. Lowndes SA, Adams A, Timms A, et al. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 2008;14(22):7526-34
51. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;2003:9(5):1666-72
52. Henry NL, Dunn R, Merjaver S, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormonerefractory prostate cancer. Oncology 2007;71(3-4):168-75
53. Lin J, Zahurak M, Beer TM, et al. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive prostate cancer. Urol Oncol 2013;31(5):581-8
54. Schneider BJ, Lee JS-J, Hayman JA, et al. Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer. Invest New Drugs 2013;31(2):435-42
55. Bruce JY, Eickhoff J, Pili R, et al. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs 2012;30(2):794-802
56. Kulke MH, Chan JA, Meyerhardt JA, et al. A prospective phase II study of 2- methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 2011;68(2):293-300
57. Zhou Q, Gustafson D, Nallapareddy S, et al. A phase I dose-escalation, safety and pharmacokinetic study of the 2- methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs 2011;29(2):340-6
58. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009;73(4):1069-76
59. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22(1):157-65
60. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROSmediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006;10(3):241-52
61. Dragovich T, Gordon M, Mendelson D, et al. Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 2007;25(13):1779-84
62. Bailey HH, Ripple G, Tutsch KD, et al. Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997;89(23):1789-96
63. Coriat R, Alexandre J, Nicco C, et al. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest 2014;124(1):262-72
64. Karlsson JOG, Kurz T, Flechsig S, et al. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct. Transl Oncol 2012;5(6):492
65. Bach SJ, Swaine D. The effect of arginase on the retardation of tumour growth. Br J Cancer 1965;19:379-86
66. Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 2010;1(4):246-51
67. Story MD, Voehringer DW, Stephens LC, Meyn RE. L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol 1993;32(2):129-33
68. Ettinger LJ, Kurtzberg J, Voute P, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176-6
69. Hays JL, Kim G, Walker A, et al. A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: early closure for safety. Mol Clin Oncol 2013;1(3):565-9
70. Ott PA, Carvajal RD, Pandit-Taskar N, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 2013;31(2):425-34
71. Tomlinson BK, Bomalaski JS, Diaz M, et al. Phase I trial of ADI-peg 20 plus docetaxel (DOC) in patients (pts) with advanced solid tumors. J Clin Oncol 2013;31(Suppl):abstract 2569
72. Yang T, Lu S, Chao Y, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010;103(7):954-60
73. Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol 1984;247(1 Pt 2):R146-53
74. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6(4):551-62
75. Liu H, Liu JY, Wu X, Zhang JT. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol 2010;1(1):69-89
76. Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013;119(2):363-70
77. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010;16(9):387-97
78. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807-12
79. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73
80. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462(7274):739-44
81. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18(6):553-67
82. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483(7390):474-8
83. Chaturvedi A, Cruz MMA, Jyotsana N, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122(16):2877-87
84. Stein E, Tallman M, Pollyea D, et al. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014. p. 5-9
85. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 2010;29(50):6509-21
86. Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX-) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011;29(1):121-6
87. Belldegrun A, Kloepfer P, Fall B, et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC - results and implications for adjuvant clinical trials. J Clin Oncol 2013;31(Suppl):abstract 4507
88. Dittrich C, Zandvliet A, Gneist M, et al. A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer 2007;96(4):559-66
89. Siegel-Lakhai W, Zandvliet A, Huitema A, et al. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Br J Cancer 2008;98(8):1320-6
90. Raftopoulos H, Escudier B, Renshaw G, et al. A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). J Clin Oncol 2004;22:4629
91. Talbot DC, von Pawel J, Cattell E, et al. A randomized phase ii pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2007;13(6):1816-22
92. Zhong C, Fan L, Yao F, et al. HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumor Biol 2014;35:4123-9
93. Han JY, Lim KY, Yu SY, et al. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensivedisease small cell lung cancer. Cancer 2011;117(10):2178-85
94. Hong JY, Nam EM, Lee J, et al. Randomized double-blinded, placebocontrolled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother Pharmacol 2014;73(1):125-30
95. Han J-Y, Lee S-H, Yoo NJ, et al. A randomized phase II. study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2011;17(6):1553-60
96. Advani AS, McDonough S, Copelan E, et al. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 2014. [Epub ahead of print]
97. Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013;13:235
98. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012;29(2):1314-27
99. Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF. Metformin and cancer therapy. Curr Opin Oncol 2012;24(1):103-8
100. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10(3):143-56
101. Ko EM, Walter P, Jackson A, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014;132(2):438-42
102. Thompson AM. Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clin Cancer Res 2014;20(10):2508-15
103. Aragón F, Perdigón G, de LeBlanc A. Modification in the diet can induce beneficial effects against breast cancer. World J Clin Oncol 2014;5(3):455